Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

The MarketWatch News Department was not involved in the creation of this content. -- New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with ...

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic ...

For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) ...

The MarketWatch News Department was not involved in the creation of this content. -- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements ...

PLAINSBORO, N.J., and BAGSVÆRD, Denmark, Oct. 20, 2025 /PRNewswire/ -- Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be presented at ...